Contact us
If you have a question or need a quotation for your project using one of our services, please just fill out the Inquiry Form on the "Contacts" page, and we will do our best to respond to your inquiry within 24 hours.
A free online tool for protein cleavage sites prediction with a chosen enzyme.
Calculate monoisotopic and average mass of a custom peptide or peptides predicted from a protein.
The cleavage specificities of selected enzymes.
A comprehensive and freely accessible resource of protein sequence and functional information.
Mass spectrum simulation tool for peptide/protein sequences. The number of charge can be custom defined.
An online tool predicts m/z values for SMS ions generated from selected fragmentation methods such as CID, ECD, or ETD. The ion type and maximum number of charge can be pre-defined.
PDB provides the most complete collection of information about the 3D structures of proteins, protein complexes and other biomolecules.
Useful links
finemapping Technology
The proprietary FineMapping technology platform was developed as the best-in-class solution for the determination of the binding site of proteins and antibodies. It consists of a suite of proprietary technologies including proteomic PTM profiling, top/middle-down HDX-MS, subzero liquid chromatography, and dedicated software analysis. These core technologies allow for unambiguous glycan identification, significantly reduced back exchange, more complete sequence coverage (~100%) and unparalleled sensitivity. All these advantages make FineMapping ideal for accurate and complete binding interface and epitope determination.
High sequence coverage is crucial for epitope mapping as the epitope may only contain a few amino acid residues. The traditional bottom-up HDX-MS workflow often results in very small peptides too hydrophilic to be retained on LC columns and is unable to detect post-translationally modified peptides such as glycopeptides. The FineMapping platform was developed to effectively tackle these limitations. When combined with our SEED technology, protein binding epitopes can be determined at single-residue resolution.
PD-1 is an important drug target for biologics development, but it is heavily glycosylated. Epitope mapping on PD-1 by traditional HDX-MS and other methods only provides incomplete information. By using the proprietary FineMapping technology, we successfully determined the epitope and paratope for Pembrolizumab (Pem) in one experiment, with complete information and amino acid level resolution.
The FineMapping platform has no limitation on antigen targets, and also works for any type of antibody/protein formats. Below are just some representative examples.
